The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer

Clinical and Experimental Metastasis

Volumn 32, Issue 8, 2015, Pages 789-798

  Hisamatsu, Takeshi ^a   Mabuchi, Seiji ^a   Sasano, Tomoyuki ^a   Kuroda, Hiromasa ^a   Takahashi, Ryoko ^a   Matsumoto, Yuri ^a   Kawano, Mahiru ^a   Kozasa, Katsumi ^a   Takahashi, Kei ^a   Sawada, Kenjiro ^a   Matsuo, Koji ^b   Tamada, Yutaka ^c   Morii, Eiichi ^a   Kitadai, Yasuhiko ^d   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Lymphangiogenesis; Lymphatic vascular endothelial progenitor cells; Ovarian cancer; VEGF C

Indexed keywords

EVEROLIMUS; PLACEBO; VASCULOTROPIN C; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; VEGFC PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHATIC SPACE INVASION; METASTASIS INHIBITION; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MICE; MULTIPROTEIN COMPLEXES; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84947495359     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-015-9751-0     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30
2. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics. CA Cancer J Clin 60(5):277–300
3. Gatta G, Lasota MB, Verdecchia A, EUROCARE Working Group (1998) Survival of European women with gynaecological tumours, during the period 1978-1989. Eur J Cancer 34(14):2218–2225
4. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365(26):2473–2483
5. Mikami M (2014) Role of lymphadenectomy for ovarian cancer. J Gynecol Oncol 25(4):279–281
6. Chan JK, Munro EG, Cheung MK et al (2007) Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109(1):12–19
7. Alitalo K (2011) The lymphatic vasculature in disease. Nat Med 17(11):1371–1380
8. Kim HS, Park NH, Chung HH et al (2008) Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Acta Obstet Gynecol Scand 87(11):1136–1142
9. Li AJ, Madden AC, Cass I et al (2004) The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92(1):211–214
10. Powless CA, Aletti GD, Bakkum-Gamez JN et al (2011) Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol 122(3):536–540
11. Matsuo K, Sheridan TB, Yoshino K et al (2012) Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med 1(2):156–164
12. Birner P, Obermair A, Schindl M et al (2001) Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 7(1):93–97
13. Weber SK, Sauerwald A, Polcher M et al (2012) Detection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancer. Int J Gynecol Cancer 22(8):1442–1448
14. Decio A, Taraboletti G, Patton V et al (2014) Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol 184(4):1050–1061
15. Ueda M, Hung YC, Terai Y et al (2005) Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin Cancer Res 11(9):3225–3232
16. Cheng D, Liang B, Li Y (2013) Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One 8(2):e55309
17. Kodama M, Kitadai Y, Tanaka M et al (2008) Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 14(22):7205–7214
18. Koukourakis MI, Giatromanolaki A, Sivridis E et al (2005) LYVE-1 immunohistochemical assessment of lymphangiogenesis in endometrial and lung cancer. J Clin Pathol 58(2):202–206
19. Bauer SM, Bauer RJ, Liu ZJ et al (2005) Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J Vasc Surg 41(4):699–707
20. Tamada Y, Aoki D, Nozawa S et al (2004) Model for paraaortic lymph node metastasis produced by orthotopic implantation of ovarian carcinoma cells in athymic nude mice. Eur J Cancer 40(1):158–163
21. Carracedo A, Ma L, Teruya-Feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065–3074
22. Di Nicolantonio F, Arena S, Tabernero J et al (2010) Deregulation of the PI3 K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120(8):2858–2866
23. Bogos K, Renyi-Vamos F, Dobos J et al (2009) High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer. Clin Cancer Res 15(5):1741–1746
24. Religa P, Cao R, Bjorndahl M et al (2005) Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood 106(13):4184–4190
25. Mabuchi S, Kuroda H, Takahashi R et al (2015) The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol 137(1):173–179
26. Kobayashi S, Kishimoto T, Kamata S et al (2007) Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98(5):726–733
27. Salven P, Mustjoki S, Alitalo R et al (2003) VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 101(1):168–172
28. Tan YZ, Wang HJ, Zhang MH et al (2014) CD34+ VEGFR-3+ progenitor cells have a potential to differentiate towards lymphatic endothelial cells. J Cell Mol Med 18(3):422–433
29. Asahara T, Takahashi T, Masuda H et al (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14):3964–3972
30. Patel V, Marsh CA, Dorsam RT et al (2011) Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 71(22):7103–7112
31. Hirashima K, Baba Y, Watanabe M et al (2010) Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 17(9):2486–2493
32. Yu G, Wang J, Chen Y et al (2009) Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15(5):1821–1829
33. Mabuchi S, Altomare DA, Connolly DC et al (2007) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67(6):2408–2413
34. Mabuchi S, Altomare DA, Cheung M et al (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13(14):4261–4270
35. Lin J, Lalani AS, Harding TC et al (2005) Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65(15):6901–6909